H. Lee Moffitt Cancer Center and Research Institute: Lung Neoplasms trials

The registry lists 34 Lung Neoplasms studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 1 are open to participants now and 19 have results posted.

Early Phase 1 1Phase 1 14Phase 2 19Phase 3 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingNCT05681780Phase 1
• Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)TerminatedNCT03406715Phase 2Results posted
• Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerCompletedNCT03215810Phase 1Results posted
• Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerCompletedNCT03043599Phase 1/2Results posted
• Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT02638090Phase 1/2Results posted
• AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung CancerCompletedNCT02513563Phase 2Results posted
• Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)CompletedNCT01999985Phase 1Results posted
• Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung CancerCompletedNCT01433172Phase 1/2Results posted
• Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target ModulationTerminatedNCT00858403Phase 2Results posted
• Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung CancerTerminatedNCT00776295Phase 2Results posted
• Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)CompletedNCT00673738Phase 2Results posted
• To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic AcidCompletedNCT00617409Phase 2Results posted
• Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant ChemTerminatedNCT00612677Phase 2Results posted
• Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung CancerCompletedNCT00601796Phase 2Results posted
• Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLCCompletedNCT00499109Phase 3Results posted
• Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung CancerTerminatedNCT00351039Phase 1/2Results posted
• Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung CancerCompletedNCT00231465Phase 2Results posted
• Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLCCompletedNCT00226590Phase 2Results posted
• Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.CompletedNCT00226577Phase 2Results posted
• Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular CorrelatesTerminatedNCT00104728Not applicableResults posted
• Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung CancerActive, not recruitingNCT06530615
• Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)SuspendedNCT06219174Phase 1/2
• Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLCCompletedNCT05873439Early Phase 1
• Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-freeCompletedNCT05362318Not applicable
• Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCTerminatedNCT04610658Phase 1
• Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerActive, not recruitingNCT03923270Phase 1
• Immunonutrition to Reduce Toxicities in Non-Small Cell Lung CancerWithdrawnNCT03628144Phase 2
• Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCActive, not recruitingNCT03611738Phase 1
• Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current SmokersActive, not recruitingNCT03598309Phase 2
• Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLCCompletedNCT03177291Phase 1
• Pilot Study of Regional Lung VentilationCompletedNCT03077113Not applicable
• Oncology Research Information Exchange Network (ORIEN) Lung Cancer StudyCompletedNCT02803333
• A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationCompletedNCT01859026Phase 1
• Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00049218Phase 1/2